DSM-Firmenich Valuation Multiples

DSM-Firmenich is valued at $29B as of November 2026, a 3.1x revenue multiple. In the last 12 months, DSM-Firmenich revenue was $11B and DSM-Firmenich EBITDA was $2.1B.

DSM-Firmenich Overview

About DSM-Firmenich

DSM-Firmenich is a global science-based company formed in 2023 through the merger of DSM, a Dutch nutrition, health, and sustainable living player, and Switzerland-based Firmenich, the third-largest player in the flavor and fragrance market. The company serves a wide range of end-consumer markets providing nutrition solutions ranging from medical and early-life nutrition, fragrances for personal-, home-, and laundry-care brands, prestige perfumes, and other ingredients for food and beverage, home, and personal care. DSM-Firmenich has nearly 30,000 employees, with more than 2,000 scientists and engineers spread across 15 research and development facilities.


Founded

2022

HQ

Switzerland

Employees

27.0K

Sectors

Financials (LTM)

Revenue: $11B
EBITDA: $2.1B

EV

$34B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

DSM-Firmenich Financials

DSM-Firmenich reported last 12-month revenue of $11B and EBITDA of $2.1B.

In the same LTM period, DSM-Firmenich generated $4.4B in gross profit, $2.1B in EBITDA, and $644M in net income.

Revenue (LTM)


DSM-Firmenich P&L

In the most recent fiscal year, DSM-Firmenich reported revenue of $10B and EBITDA of $1.8B.

DSM-Firmenich is unprofitable as of last fiscal year, with gross margin of 39%, EBITDA margin of 17%, and net margin of (12%).

See analyst estimates for DSM-Firmenich
LTMLast FY202320242025202620272028
Revenue$11B$10B$12B$11B$10B
Gross Profit$4.4B$3.9B$3B$4.1B$3.9B
Gross Margin40%39%25%39%39%
EBITDA$2.1B$1.8B$472M$1.7B$1.8B
EBITDA Margin19%17%4%16%17%
EBIT Margin9%7%(5%)6%7%
Net Profit$644M($1.2B)$2.5B$290M($1.2B)
Net Margin6%(12%)20%3%(12%)
Net Debt-$3.5B---

Financial data powered by Morningstar, Inc.

DSM-Firmenich Stock Performance

DSM-Firmenich has current market cap of $29B, and enterprise value of $34B.

Market Cap Evolution


DSM-Firmenich's stock price is $118.70.

DSM-Firmenich share price decreased by 0.5% in the last 30 days, and increased by 44.8% in the last year.

DSM-Firmenich has an EPS (earnings per share) of $-4.95.

See more trading valuation data for DSM-Firmenich
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$34B$29B0.2%-0.5%6.7%44.8%$-4.95

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

DSM-Firmenich Valuation Multiples

DSM-Firmenich trades at 3.1x EV/Revenue multiple, and 16.4x EV/EBITDA.

See NTM and 2027E valuation multiples for DSM-Firmenich

EV / Revenue (LTM)


DSM-Firmenich Financial Valuation Multiples

As of November 13, 2026, DSM-Firmenich has market cap of $29B and EV of $34B.

DSM-Firmenich has a P/E ratio of 45.0x.

LTMLast FY202320242025202620272028
EV/Revenue3.1x3.4x2.8x3.2x3.4x
EV/EBITDA16.4x19.5x72.4x20.3x19.5x
EV/EBIT33.0x48.3x(58.0x)53.4x48.3x
EV/Gross Profit7.8x8.6x11.3x8.3x8.6x
P/E45.0x(24.0x)11.7x99.9x(24.0x)
EV/FCF41.1x52.0x59.2x31.3x52.0x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified DSM-Firmenich Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

DSM-Firmenich Margins & Growth Rates

DSM-Firmenich grew revenue by 2% and EBITDA by 14% in the last fiscal year.

In the most recent fiscal year, DSM-Firmenich reported gross margin of 39%, EBITDA margin of 17%, and net margin of (12%).

See estimated margins and future growth rates for DSM-Firmenich

DSM-Firmenich Margins

Last FY202420252026202720282029
Gross Margin39%39%39%36%
EBITDA Margin17%16%17%19%
EBIT Margin7%6%7%9%
Net Margin(12%)3%(12%)6%
FCF Margin6%10%6%8%

DSM-Firmenich Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth2%(15%)(4%)2%
Gross Profit Growth(5%)36%(4%)(5%)
EBITDA Growth14%257%4%14%
EBIT Growth35%(209%)10%35%
Net Profit Growth(151%)(88%)(516%)(151%)
FCF Growth28%89%(40%)28%

Data powered by FactSet, Inc. and Morningstar, Inc.

DSM-Firmenich Operational KPIs

DSM-Firmenich's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.

DSM-Firmenich's Rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

DSM-Firmenich's Rule of X is 25% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for DSM-Firmenich
LTMLast FY202320242025202620272028
Rule of 4018%21%---
Bessemer Rule of X15%25%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.1M---
S&M Expenses to Revenue-14%14%16%14%
G&A Expenses to Revenue-10%10%9%10%
R&D Expenses to Revenue7%8%6%9%8%
Opex to Revenue-32%29%33%32%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

DSM-Firmenich Competitors

DSM-Firmenich competitors include PPG, Novonesis, Qnity Electronics, OMV, Wanhua Chemical, Ems-Chemie, Dow, Ningxia Baofeng Energy Group, International Flavors & Fragrances and DuPont.

Most DSM-Firmenich public comparables operate across Chemicals.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
PPG$16B$2.7B2.1x2.0x12.6x11.7x
Novonesis$4.7B$1.5B7.4x7.0x22.6x18.5x
Qnity Electronics$4.8B$1.4B6.2x5.2x21.1x16.9x
OMV$27B$5.6B1.3x1.1x6.4x3.8x
Wanhua Chemical$30B$5.2B1.6x1.3x9.2x7.0x
Ems-Chemie$2.4B$749M9.8x9.6x30.8x29.3x
Dow$40B$1B1.0x0.9x38.4x6.8x
Ningxia Baofeng Energy Group$7.2B$2.6B3.7x3.0x10.2x6.8x

This data is available for Pro users. Sign up to see all DSM-Firmenich competitors and their valuation data.

Start Free Trial

Acquisitions by DSM-Firmenich

DSM-Firmenich has acquired 2 companies to date.

Last acquisition by DSM-Firmenich was on April 19th 2023. DSM-Firmenich acquired Adare Biome for $297M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by DSM-Firmenich

Adare Biome
DSM
Description
Adare Biome develops, produces and sells postbiotic ingredients and is based in Houdan, France. It was part of Adare Pharma Solutions until dsm-firmenich acquired it in 2023.
DSM, formally Koninklijke DSM N.V. or Royal DSM, was a Dutch multinational active in health, nutrition and materials, listed on Euronext Amsterdam. The Dutch state formed it in 1902 to mine coal reserves in southern Limburg, and its name comes from Dutch State Mines; by the time the last mine closed in 1973 it had diversified into commodity chemicals and petrochemicals. It later concentrated on nutritional and specialty food ingredients and performance materials such as engineering plastics and Dyneema fibre, earning revenue from product sales to food, feed, pharmaceutical and industrial customers. At the end of 2017 DSM employed 21,054 people in about 50 countries, and it posted net sales of €8.632 billion in 2018 and €9.204 billion in 2021. In 2013 it contributed its DSM Pharmaceutical Products business to a new contract manufacturer formed with JLL Partners around Patheon, keeping a 49% stake. In May 2023 DSM merged with the Swiss company Firmenich to form dsm-firmenich.
HQ CountryFranceNetherlands
HQ City
Paris
Heerlen
Deal Date19 Apr 20233 Apr 2023
Valuation$297Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all DSM-Firmenich acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by DSM-Firmenich

DSM-Firmenich has invested in 1 company to date.

Latest investment by DSM-Firmenich was on March 13th 2024. DSM-Firmenich invested in Cynomys in their $2M Seed round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by DSM-Firmenich

Cynomys
Description
Cynomys is an Italian IoT company that patented sensors for monitoring over 30 parameters in livestock farms including welfare, emissions, and resource use. Launched in 2018 from Modena, the cloud-connected devices track temperature, humidity, feed intake, and ammonia levels for cattle, swine, and poultry operations. Cynomys serves feed producers and large farms in Italy, Spain, France, Netherlands, and Mexico, optimizing productivity and sustainability via remote dashboards.
HQ CountryItaly
HQ City
Ronco Scrivia
Deal Date13 Mar 2024
RoundSeed
Raised$2M
InvestorsFarming Future; PLUS9; DSM-Firmenich; SVG Ventures; Levante Capital
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all DSM-Firmenich investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About DSM-Firmenich

Who are competitors of DSM-Firmenich?DSM-Firmenich main competitors include PPG, Novonesis, Qnity Electronics, OMV, Wanhua Chemical, Ems-Chemie, Dow, Ningxia Baofeng Energy Group, International Flavors & Fragrances, DuPont.

See public comps similar to DSM-Firmenich

Lists including DSM-Firmenich

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial